IN2014DN07913A - - Google Patents

Info

Publication number
IN2014DN07913A
IN2014DN07913A IN7913DEN2014A IN2014DN07913A IN 2014DN07913 A IN2014DN07913 A IN 2014DN07913A IN 7913DEN2014 A IN7913DEN2014 A IN 7913DEN2014A IN 2014DN07913 A IN2014DN07913 A IN 2014DN07913A
Authority
IN
India
Prior art keywords
relates
rosacea
vesicular
administering
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
John Mayo
William Henry
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Publication of IN2014DN07913A publication Critical patent/IN2014DN07913A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fodder In General (AREA)
IN7913DEN2014 2012-03-29 2013-03-28 IN2014DN07913A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
PCT/EP2013/056694 WO2013144289A1 (en) 2012-03-29 2013-03-28 Vesicular formulations

Publications (1)

Publication Number Publication Date
IN2014DN07913A true IN2014DN07913A (cs) 2015-04-24

Family

ID=46159988

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7913DEN2014 IN2014DN07913A (cs) 2012-03-29 2013-03-28

Country Status (19)

Country Link
US (1) US9555051B2 (cs)
EP (1) EP2830630A1 (cs)
JP (1) JP2015511618A (cs)
KR (1) KR20150004798A (cs)
CN (1) CN104349782A (cs)
AU (1) AU2013241701A1 (cs)
BR (1) BR112014024033A8 (cs)
CA (1) CA2867749A1 (cs)
CL (1) CL2014002547A1 (cs)
CO (1) CO7121334A2 (cs)
EA (1) EA038899B1 (cs)
GB (2) GB201205642D0 (cs)
IL (1) IL234747A0 (cs)
IN (1) IN2014DN07913A (cs)
MX (1) MX2014011516A (cs)
NZ (1) NZ700472A (cs)
PH (1) PH12014502065A1 (cs)
SG (1) SG11201406144TA (cs)
WO (1) WO2013144289A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120129864A (ko) 2009-08-21 2012-11-28 타겟티드 딜리버리 테크놀러지스 리미티드 소포성 제형
EA033590B1 (ru) * 2014-12-23 2019-11-07 Camurus Ab Препараты с контролируемым высвобождением
EP3316857B1 (en) 2015-06-30 2021-08-04 Sequessome Technology Holdings Limited Multiphasic compositions
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US20240299378A1 (en) * 2021-02-25 2024-09-12 Exinov Emulsion for use in the treatment of rosacea

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
EP0238554A4 (en) 1985-09-27 1987-10-27 Univ California SYSTEM FOR TRANSDERMAL DELIVERY OF MEDICAMENTS TO LIPOSOMES.
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
JP3765579B2 (ja) 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
ES2107668T3 (es) 1992-07-08 1997-12-01 Dianorm G Maierhofer Gmbh Liposomas, procedimiento para su preparacion y su uso en la elaboracion de un medicamento.
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
JP3867123B2 (ja) * 1997-11-19 2007-01-10 インテンディス ゲゼルシャフト ミット ベシュレンクテル ハフツング アゼライン酸を含む組成物
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CA2345355A1 (en) 1998-09-01 2000-03-09 Idea Ag Electrically controlled transport of charged penetrants across barriers
MXPA01006424A (es) 1998-12-23 2002-06-04 Idea Ag Formulacion mejorada para aplicacion topica no invasiva in vivo.
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
AU2001248301A1 (en) 2000-04-12 2001-10-23 Liplasome Pharma A/S Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
TNSN03127A1 (fr) 2001-05-31 2005-12-23 Pharmacia Corp Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique
EP1406571A4 (en) 2001-06-25 2007-05-30 Depuy Int Ltd LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHROSIS JOINTS
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
AU2003233396B2 (en) 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
EA010407B1 (ru) 2002-10-11 2008-08-29 Идеа Аг Фармацевтические препараты для проникновения через полунепроницаемые барьеры и для неинвазивного введения лекарственных средств in vivo
US20070160656A1 (en) 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
BRPI0412882A (pt) 2003-07-21 2006-10-03 Vasogen Ireland Ltd uso de uma quantidade de corpos farmaceuticamente aceitáveis que portam um número eficaz de grupos contendo fosfato
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
KR20070086045A (ko) 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
AU2006284990B2 (en) 2005-08-29 2011-01-06 Sepsicure L.L.C. Method for treatment or prevention of conditions caused by gram-positive bacteria
ES2511772T3 (es) 2005-12-20 2014-10-23 Cenestra, Llc Formulaciones de ácidos grasos omega-3
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
EP2079442B1 (en) 2006-09-28 2016-07-27 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
JP4732307B2 (ja) * 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
RU2011136624A (ru) 2009-02-05 2013-03-10 Тарджетед Деливери Текнолоджиз Лимитед Способы уменьшения пролиферации и жизнеспособности микробных агентов
SG176297A1 (en) 2009-06-03 2012-01-30 John Charles Mayo Formulations for the treatment of deep tissue pain
KR20120129864A (ko) 2009-08-21 2012-11-28 타겟티드 딜리버리 테크놀러지스 리미티드 소포성 제형
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
SG11201600424VA (en) 2013-07-31 2016-02-26 Sequessome Technology Holdings Ltd Vesicles

Also Published As

Publication number Publication date
GB2515440A (en) 2014-12-24
JP2015511618A (ja) 2015-04-20
KR20150004798A (ko) 2015-01-13
NZ700472A (en) 2016-02-26
CL2014002547A1 (es) 2015-03-27
MX2014011516A (es) 2015-04-08
SG11201406144TA (en) 2014-10-30
US20150057249A1 (en) 2015-02-26
CA2867749A1 (en) 2013-10-03
EA038899B1 (ru) 2021-11-03
GB201205642D0 (en) 2012-05-16
GB2515440B (en) 2017-02-08
CN104349782A (zh) 2015-02-11
US9555051B2 (en) 2017-01-31
GB201419075D0 (en) 2014-12-10
IL234747A0 (en) 2014-11-30
CO7121334A2 (es) 2014-11-20
EP2830630A1 (en) 2015-02-04
BR112014024033A2 (cs) 2017-06-20
AU2013241701A1 (en) 2014-10-16
BR112014024033A8 (pt) 2017-07-25
WO2013144289A1 (en) 2013-10-03
EA201491581A1 (ru) 2015-02-27
PH12014502065A1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
GB201103062D0 (en) Method
PH12015502075B1 (en) Treatment of cataplexy
GB201118656D0 (en) New compounds
TN2015000278A1 (en) Autotaxin inhibitors
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX349004B (es) Nuevos compuestos.
MX366899B (es) Nuevos compuestos.
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
UA118610C2 (uk) Спіроциклічні інгібітори катепсину c
PH12014502032A1 (en) Treatment of brain cancer
PH12014502558A1 (en) Drug for preventing and/or treating polycystic kidney disease
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
PH12014502065A1 (en) Vesicular formulations
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
IN2014DN03010A (cs)
IN2013MU03118A (cs)
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
HK1202249A1 (en) Vesicular formulations